High‐dose transdermal nicotine in Parkinson's disease patients: a randomized, open‐label, blinded‐endpoint evaluation phase 2 study

Publisher： John Wiley & Sons Inc

E-ISSN： 1468-1331|25|1|120-127

ISSN： 1351-5101

Source： EUROPEAN JOURNAL OF NEUROLOGY, Vol.25, Iss.1, 2018-01, pp. : 120-127

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase II, open‐label evaluation of cysteamine tolerability in patients with Huntington's disease

By  

MOVEMENT DISORDERS, Vol. 30, Iss. 2, 2015-02 ,pp. : 288-289

John Wiley & Sons Inc

Access to resources Recommend Favorite

Modest blood pressure reduction with valsartan in acute ischemic stroke: a prospective, randomized, open‐label, blinded–end‐point trial

By  

INTERNATIONAL JOURNAL OF STROKE, Vol. 10, Iss. 5, 2015-07 ,pp. : 745-751

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study

By Choi Seong Hye   Park Kyung Won   Na Duk L.   Han Hyun Jeong   Kim Eun-Joo   Shim Yong S.   Lee Jae-Hong    

Current Medical Research and Opinion, Vol. 27, Iss. 7, 2011-07 ,pp. : 1375-1383

Informa Healthcare

Access to resources Recommend Favorite

CCH Phase 3 Open‐Label Study

By  

THE JOURNAL OF SEXUAL MEDICINE, Vol. 12, Iss. 1, 2015-01 ,pp. : 248-258

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of once‐weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once‐daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open‐label, phase III, non‐inferiority study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 10, 2015-10 ,pp. : 994-1002

John Wiley & Sons Inc

Access to resources Recommend Favorite